Keywords: Azithromycin; COVID-19; SARS-CoV-2; antivirals; cytokine release syndrome; immunomodulation; pneumonia. Methods
We recommend formal clinical trials of azithromycin in its prepackaged form at the first sign of COVID-19 infection in adults and children, using an initial adult dose of 500 mg followed by 250 mg per day for 4 days, a total cumulative dose of 1
Azithromycin has rapidly been adopted as a repurposed drug for the treatment of COVID-19, despite the lack of high-quality evidence
Azithromycin (Zithromax) is the most consistently studied antibiotic for use in treating patients infected with the SARS-CoV-2 virus; it does not improve mortality after 28 days
Azithromycin is widely available and
Unfortunately, the virus has far from
CDC is considering a shift its Covid-19 isolation guidance to say that people no longer need to isolate once they have been fever-free for 24 hours and their symptoms